ROCKVILLE, Md., Jan. 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the Biotech Showcase™ 2015 Conference next week in San Francisco, as follows:
Date: Tuesday, January 13, 2015
Time: 2:00 p.m. (PT) / 5:00 p.m. (ET)
Location: Parc 55 Wyndham San Francisco Union Square Hotel – Room: Mission II (4th Floor)
A live webcast of Synthetic Biologics’ presentation may be accessed by logging onto the internet at http://edge.media-server.com/m/p/pqjict2k. After the presentation, a replay will be archived and accessible for 90 days at the same website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gastrointestinal (GI) microflora from the effects of intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS) and a monoclonal antibody combination for the treatment of Pertussis being developed in collaboration with Intrexon Corporation (NYSE: XON). In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-biotech-showcase-2015-conference-300016845.html
SOURCE Synthetic Biologics, Inc.
Released January 7, 2015